Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430917 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of J147 in Acute Ischemic Stroke
A Phase 2 study, sponsored by Abrexa Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT07430917: Clinical Trial Phase 2 study, sponsored by Abrexa Pharmaceuticals.
NCT07430917 is a Phase 2 study that has not yet begun recruiting, run by Abrexa Pharmaceuticals. The registered enrollment target is 196 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07430917, a Phase 2 study, has not yet begun recruiting, sponsored by Abrexa Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clear the blood clot to those who don't receive J147. Participants will be asked to undergo a series of three to four magnetic resonance imaging (MRI) brain scans, and blood samples will be collected at several time points. Participants will also be evaluated to measure several aspects of brain function.
Interventions
- OTHER Placebo
- DRUG J147 Emulsion for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07430917
The ClinicalTrials.gov registry entry for NCT07430917 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abrexa Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07430917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07430917 about?
NCT07430917 is a clinical study titled "Safety and Efficacy of J147 in Acute Ischemic Stroke". The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clea...
What is the current status of trial NCT07430917?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2026-04-20. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07430917?
The interventions under investigation include: Placebo (OTHER), J147 Emulsion for Injection (DRUG).
Who is sponsoring clinical trial NCT07430917?
This trial is sponsored by Abrexa Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.